维速达尔(Visudyne,注射用维替泊芬)(图1)是诺华公司研制的一种来源于卟啉的第二代光敏药物。应用维速达尔的光动力疗法是治疗脉络膜新生血管形成(CNV)的重要进展之一。该产品于1999年12月16日首先在瑞士获得上市许可,2000年4月13日被美国食品和药品管理局(FDA)批准。2005年在中国上市。目前维速达尔已在140多个国家临床应用。 Visudyne (vertexporphine for injection) (Figure 1) is a second-generation photosensitizer from Novartis that is derived from porphyrin. One of the major advances in the treatment of choroidal neovascularization (CNV) is the application of photodynamic therapy with Veldar. The product was first licensed in Switzerland on December 16, 1999 and was approved by the U.S. Food and Drug Administration (FDA) on April 13, 2000. 2005 in China market. At present, Viktor has clinical application in more than 140 countries.